Children who miss diphtheria, tetanus toxoid, and acellular pertussis (DTaP) vaccine doses are at more likely to develop whooping cough, according to a study in JAMA Pediatrics.
Children who miss diphtheria, tetanus toxoid, and acellular pertussis (DTaP) vaccine doses are at more likely to develop whooping cough, according to a study in JAMA Pediatrics.
Jason Glanz, PhD, of Kaiser Permanente Colorado, and colleagues studied the correlation between undervaccination and pertussis in children 3 to 36 months old. They examined data from 8 managed care organizations in the Vaccine Safety Datalink between 2004 and 2010. For purposes of the study, undervaccination for the DTaP vaccine was defined as missing or delaying 1 or more of the first 4 doses by the recommended age.
They found that children who missed 3 doses of the DTaP vaccine were nearly 19 times more likely to develop pertussis than those who received the recommended number of doses. Children who missed 4 doses were 28 times more likely to develop whooping cough.
Last year, more than 41,000 cases of whooping cough were reported to the U.S. Centers for Disease Control and Prevention. Texas and California have reported whooping cough epidemics. Some medical experts attribute the increased incidence to parents who opt not to get their children the DTaP vaccine. Healthcare barriers and medical contraindication have also contributed to the trend.
In the study, 47% of the whooping cough cases belonged to children who were undervaccinated for DTaP. Nearly 30% of the undervaccinated children who developed pertussis are believed to have parents who “intentionally refused or delayed vaccine doses for personal, nonmedical reasons," the study report said.
Glanz and his colleagues believe 36% of identified pertussis cases identified in the study could have been prevented with on-time vaccination.
Iowa Expands PBM Legislation to Address Concerns of Independent Pharmacies
May 16th 2025A new law in Iowa, if signed by the governor, will mandate 100% pass-through of rebates, increased financial transparency, and a minimal payment for pharmacies. Critics say it will be the most costly mandate in the state’s history.
Read More
Is Arkansas’ New PBM Law the Right Path Forward for Reform? No One Knows Yet
May 9th 2025It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are unsure about the impact of Arkansas’ law banning PBMs from owning pharmacies.
Read More